MicroPort CRM Raises $150 Million for Implantable CRM Devices
publication date: Jul 27, 2021
MicroPort Cardiac Rhythm Management closed a $150 million Series C financing including $20 million from Hillhouse and $47 million from MicroPort® Scientific, its parent. MicroPort CRM makes implantable pacemaker and defibrillator devices to manage cardiac rhythm disorders. In 2017, MicroPort acquired the CRM business of Italy's Liva Nova for $190 Million. MicroPort® CRM is headquartered in Clamart, a suburb of Paris, with R&D teams in Clamart and Shanghai. The parent, MicroPort® Scientific, is a global medical device company, headquartered in Shanghai. More details....
Stock Symbol: (HK: 00853)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.